13F Pro Quality Score

67.9/100

Rank #442 of 2,879 stocksTOP 25%

View Industrials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.6/100

Profitability

81.4/100

Balance Sheet

65.9/100

Earnings Quality

96.5/100

Free Cash Flow

82.8/100

Institutional Flow

58.6/100

Revenue Scale

16.0/100

Dilution Risk

25.3/100

PAYS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Paysign, Inc. (PAYS), a Industrials sector company. 13F Pro's AI-powered ranking engine scores PAYS at 67.9/100 on a 32-signal composite quality model, placing it at rank #442 of 2,879 stocks — the top 25% of the AI-ranked universe. PAYS scores in the top quartile across earnings quality (96.5), revenue growth (89.6), free cash flow (82.8). Areas of concern include revenue scale (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Paysign, Inc. reports quarterly revenue of $28.0M, net income of $5.4M, free cash flow of $18.5M. Top institutional holders of PAYS by reported 13-F value include Topline Capital Management,, BlackRock,, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT,, based on the most recent SEC filings. PAYS trades on the Nasdaq exchange and files with the SEC under CIK 1496443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PAYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Paysign, Inc. directly from SEC EDGAR. Paysign, Inc.'s 13F Pro composite quality score has ranged between 22 and 68 since 2022, currently 67.9 — an improving long-term trajectory across 29 quarterly and live scoring snapshots.

Fun facts about Paysign, Inc.

Quirks, history, and lore behind PAYS — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. financial technology company · small-cap · listed on Nasdaq · headquartered in Nevada.
  • 2
    The Numbers
    Annual revenue in the range of tens of millions of dollars — not a giant, but a profitable niche player in the prepaid debit card processing space.
  • 3
    The History
    Founded in the late 1990s, the company grew by targeting industries that the traditional banking world largely ignored or underserved.
  • 4
    The Secret
    Its bread and butter is administering prepaid card programs for tribal gaming casinos and pharmaceutical patient-assistance programs — a very specific lane.
  • 5
    The Lore
    It built a loyal foothold by helping casino patrons access cash and winnings without ever touching a traditional bank account — ATM lines at Vegas get very long.
  • 6
    The Giveaway
    Its ticker is literally a four-letter synonym for getting paid, and its whole business is making sure people — from casino floors to pharmaceutical patients — can collect their money on a card.
▶ Think you know your stocks? Play the Daily Ticker

What's Driving PAYS's Business? Latest 10-Q Breakdown

AI-extracted from Paysign, Inc.'s 10-Q filed 2026-05-13 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Paysign revenue surged 50.8% YoY to $28.0M in Q1 2026, driven by 81.9% growth in pharma patient affordability programs and 24.9% growth in plasma card volumes.

Biggest Revenue Drivers

Total revenue: $28.0M+50.8% YoY

Pharma industry$15.7M+81.9% YoY

45 net pharma patient affordability programs launched in prior twelve months driving setup fees, monthly management fees, claim processing fees and other billable services.

Plasma industry$11.7M+24.9% YoY

89 net plasma centers added during prior twelve-month period and increase in plasma donations and dollars loaded to cards as market returned to normalized growth.

Other$0.6M+7.2% YoY

Growth and usage in payroll, retail and corporate incentive programs; includes breakage and settlement income.

Largest Expense Items

Cost of revenues$9.8M+42.2% YoY

Increased call center support (~$901K), network/related fees (~$1.8M) from program expansion, and sales commission expense (~$266K).

Selling, general and administrative$8.9M+20.5% YoY

Compensation (+$180K), stock-based compensation (+$612K), platform security investments, rent and conferences; offset by lower acquisition costs.

Depreciation and amortization$2.6M+46.4% YoY

Amortization of Gamma intangible assets, continued capitalization of software development, and equipment purchases for platform enhancements.

Watch Items from the Filing

  • Two pharma patient affordability customers represented 16% and 15% of accounts receivable at Q1 2026; one customer represented 31% at year-end 2025. High customer concentration risk in growing pharma segment.
  • Excess cash maintained with single financial institution is $3.5M above FDIC insured limits at Q1 2026 vs. $1.4M at year-end 2025; company relies on reciprocal deposit network for FDIC coverage.
  • Gamma Innovation acquisition contingent earn-out of up to $990K in stock based on achieving gross revenue performance targets through March 2030; earn-out revised downward from $3.2M during 2025.
  • Pharma claims processed increased 49% YoY; company is highly dependent on pharma patient affordability programs which now represent 56% of total revenue.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Revenue

Q1 2026

$28.0M

Net Income

Q1 2026

$5.4M

Free Cash Flow

Q1 2026

$18.5M

D/E Ratio

Q1 2026

0.11

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+40.5% YoY
$82.0MFY 2025
FY22 $38.0MFY23 $47.3MFY24 $58.4MFY25 $82.0M

Net Income

+97.9% YoY
$7.6MFY 2025
FY22 $1.0MFY23 $6.5MFY24 $3.8MFY25 $7.6M

Operating Income

+620.8% YoY
$7.4MFY 2025
FY22 $344.3KFY23 $-167.3KFY24 $1.0MFY25 $7.4M

EPS (Diluted)

+85.7% YoY
$0.13FY 2025
FY22 $0.02FY23 $0.12FY24 $0.07FY25 $0.13

Total Assets

+54.3% YoY
$276.3MFY 2025
FY22 $108.2MFY23 $146.6MFY24 $179.0MFY25 $276.3M

Total Debt

$8.0MFY 2025
FY22 FY23 FY24 $0.00FY25 $8.0M

Op. Cash Flow

+128.6% YoY
$52.5MFY 2025
FY22 $25.3MFY23 $27.6MFY24 $22.9MFY25 $52.5M

AI Insight: PAYS Financial Trends

Revenue accelerated 22% year-over-year to $28M in Q1 2026 while operating income doubled to $7M, signaling improved unit economics.

Revenue grew from $19M (Q1 2025) to $28M (Q1 2026), +47% YoY; operating income expanded from $2M to $7M over same period.

Net income surged to $5M in Q1 2026 versus $1M–$3M prior quarters; operating cash flow reached $48M in Q4 2025.

Total debt declined from $10M (Q1 2025) to $6M (Q1 2026); equity strengthened to $55M, improving leverage profile.

Net income volatility persists: $5M in Q1 2026 but only $1M in Q2/Q4 2025 despite stable/rising revenue—operational consistency unclear.

Operating cash flow highly erratic ($-20M to $48M range); Q1 2026 spike may not sustain without corroboration next quarter.

AI Insight: PAYS Ratio Trends

Q1 2026 profitability surged dramatically—operating margin jumped to 23.8% and ROIC reached 43.6%, signaling a major operational inflection.

Operating margin expanded from 8.2% in Q4 2025 to 23.8% in Q1 2026; NPM rose from 6.0% to 19.4% same period.

ROIC climbed to 43.6% in Q1 2026 from 13.1% in Q4 2025, highest in dataset; ROA reached 7.0%, best on record.

Leverage remained modest at 0.11 D/E in Q1 2026, down from 0.17–0.25 range in prior four quarters.

Q1 2026 metrics represent single-quarter peak; sustainability unclear given Q2–Q4 2025 volatility (OpMargin 7.3–8.2%, ROIC 11.5–13.1%).

ROE and ROA remain subject to quarterly swings; TTM ROE 18.9% lags Q1 2026's 39.6%, suggesting normalization risk.

Get alerted when PAYS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Paysign, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put PAYS on your watchlist

Track score changes the day Paysign, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is PAYS a good stock to buy?

13F Pro's AI-powered analysis of Paysign, Inc. (PAYS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PAYS are available on the PAYS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PAYS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PAYS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Paysign, Inc.'s investment landscape.